Charles Schwab Investment Management Inc Zentalis Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 406,210 shares of ZNTL stock, worth $1.47 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
406,210
Previous 468,413
13.28%
Holding current value
$1.47 Million
Previous $1.92 Million
22.19%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
67.9MCall Options Held
48.5KPut Options Held
89.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$50.7 Million2.45% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$31 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$17.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$16.7 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$11.3 Million2.71% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $207M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...